Clinical Trial Update: Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study of Autologous MSC-NTF Cells in Patients With ALS [Phase 2]

View source ↗

Summary

Phase 2 randomized, double-blind, placebo-controlled multicenter study of autologous MSC-NTF cells in amyotrophic lateral sclerosis has completed with results p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyotrophic Lateral Sclerosis

Drugs mentioned

• Autologous MSC-NTF Cells

Snippet

Sponsor: Brainstorm-Cell Therapeutics | Conditions: Amyotrophic Lateral Sclerosis (ALS) | Phase 2 | Status: COMPLETED | Results posted: 2024-06-06